Published in Proc Natl Acad Sci U S A on October 11, 2004
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol (2008) 6.90
Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem (2009) 3.88
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A (2007) 3.60
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
Chemical probes for histone-modifying enzymes. Nat Chem Biol (2008) 3.30
Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov (2013) 2.16
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem (2008) 2.12
Fluorous-based small-molecule microarrays for the discovery of histone deacetylase inhibitors. Angew Chem Int Ed Engl (2007) 2.11
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem (2008) 2.09
Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc Natl Acad Sci U S A (2007) 2.03
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep (2007) 2.01
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov (2009) 2.00
Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol (2007) 1.93
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs (2010) 1.79
Isoform-selective histone deacetylase inhibitors. Chem Soc Rev (2008) 1.72
The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci U S A (2006) 1.71
Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta (2008) 1.69
Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Biochemistry (2008) 1.68
Ketone bodies as signaling metabolites. Trends Endocrinol Metab (2013) 1.37
Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr Opin Struct Biol (2011) 1.35
A genome-wide screen for modifiers of transgene variegation identifies genes with critical roles in development. Genome Biol (2008) 1.35
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta (2010) 1.35
Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. Expert Opin Investig Drugs (2009) 1.28
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (2015) 1.25
Histone acetylation in drug addiction. Semin Cell Dev Biol (2009) 1.24
The role of histone deacetylases in prostate cancer. Epigenetics (2008) 1.21
Activation and inhibition of histone deacetylase 8 by monovalent cations. J Biol Chem (2009) 1.18
On the inhibition of histone deacetylase 8. Bioorg Med Chem (2010) 1.18
Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography. ACS Chem Neurosci (2010) 1.17
A proton-shuttle reaction mechanism for histone deacetylase 8 and the catalytic role of metal ions. J Am Chem Soc (2010) 1.14
Post-training intrahippocampal inhibition of class I histone deacetylases enhances long-term object-location memory. Learn Mem (2011) 1.14
Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Res (2012) 1.12
Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem (2009) 1.11
Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. Mol Cell Biol (2006) 1.11
Histone deacetylase inhibitors through click chemistry. J Med Chem (2008) 1.10
Evolution of the arginase fold and functional diversity. Cell Mol Life Sci (2008) 1.09
Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Chem Biol (2010) 1.09
HDAC8 substrates: Histones and beyond. Biopolymers (2013) 1.08
Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. J Exp Med (2009) 1.08
Trans-regulation of histone deacetylase activities through acetylation. J Biol Chem (2009) 1.06
K+ efflux is required for histone H3 dephosphorylation by Listeria monocytogenes listeriolysin O and other pore-forming toxins. Infect Immun (2011) 1.04
Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis (2008) 1.04
Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides. J Med Chem (2009) 1.02
Transcription and beyond: the role of mammalian class I lysine deacetylases. Chromosoma (2013) 1.01
Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem (2008) 1.00
Discovery of histone deacetylase 8 selective inhibitors. Bioorg Med Chem Lett (2011) 0.99
Histone deacetylase 8 is required for centrosome cohesion and influenza A virus entry. PLoS Pathog (2011) 0.99
Expression, purification, assay, and crystal structure of perdeuterated human arginase I. Arch Biochem Biophys (2007) 0.98
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer (2007) 0.98
Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bioorg Med Chem Lett (2007) 0.98
Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. PLoS One (2012) 0.98
Macrocyclic histone deacetylase inhibitors. Curr Top Med Chem (2010) 0.98
Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog (2013) 0.97
On the function of the internal cavity of histone deacetylase protein 8: R37 is a crucial residue for catalysis. Bioorg Med Chem Lett (2011) 0.97
Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel. J Am Chem Soc (2011) 0.97
Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function . Biochemistry (2010) 0.96
Drosophila histone deacetylase-3 controls imaginal disc size through suppression of apoptosis. PLoS Genet (2008) 0.96
Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol Biol (2011) 0.95
Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer. Pharm Pat Anal (2012) 0.94
Flexibility of Catalytic Zinc Coordination in Thermolysin and HDAC8: A Born-Oppenheimer ab initio QM/MM Molecular Dynamics Study. J Chem Theory Comput (2009) 0.94
Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors. J Med Chem (2008) 0.93
Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Curr Top Med Chem (2009) 0.93
Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis (2009) 0.93
Small molecule inhibitors of zinc-dependent histone deacetylases. Neurotherapeutics (2013) 0.91
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
Biological targets and mechanisms of action of natural products from marine cyanobacteria. Nat Prod Rep (2015) 0.90
Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors. Anal Biochem (2010) 0.90
An active site tyrosine residue is essential for amidohydrolase but not for esterase activity of a class 2 histone deacetylase-like bacterial enzyme. Biochem J (2007) 0.89
Inhibition and mechanism of HDAC8 revisited. J Am Chem Soc (2014) 0.88
Targeting Histone Deacetylases in Diseases: Where Are We? Antioxid Redox Signal (2014) 0.88
Discovery and mechanism of natural products as modulators of histone acetylation. Curr Drug Targets (2012) 0.87
Histone Deacetylases in Bone Development and Skeletal Disorders. Physiol Rev (2015) 0.87
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Cell Death Dis (2014) 0.86
Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures. J Am Chem Soc (2009) 0.86
Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.86
Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8. Biochemistry (2015) 0.86
The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. Bioorg Med Chem Lett (2011) 0.85
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST). PLoS One (2015) 0.85
The role of dietary histone deacetylases (HDACs) inhibitors in health and disease. Nutrients (2014) 0.85
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. ACS Med Chem Lett (2013) 0.84
The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position. Bioorg Med Chem Lett (2012) 0.83
Design and synthesis of novel hybrid benzamide-peptide histone deacetylase inhibitors. Bioorg Med Chem Lett (2009) 0.83
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer (2008) 0.83
HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine. ACS Chem Biol (2016) 0.82
General Base-General Acid Catalysis in Human Histone Deacetylase 8. Biochemistry (2016) 0.82
The promise and perils of HDAC inhibitors in neurodegeneration. Ann Clin Transl Neurol (2014) 0.81
Biochemical and Structural Characterization of HDAC8 Mutants Associated with Cornelia de Lange Syndrome Spectrum Disorders. Biochemistry (2015) 0.81
SLITHER: a web server for generating contiguous conformations of substrate molecules entering into deep active sites of proteins or migrating through channels in membrane transporters. Nucleic Acids Res (2009) 0.80
Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations. J Mol Model (2011) 0.80
Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups. Eur J Med Chem (2014) 0.80
Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design. J Med Chem (2014) 0.80
CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1. Epigenetics (2012) 0.80
Inhibition of histone deacetylases by trans-cinnamic acid and its antitumor effect against colon cancer xenografts in athymic mice. Mol Med Rep (2016) 0.79
Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich's Ataxia. Front Neurol (2015) 0.79
HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review). Oncol Lett (2014) 0.79
Quantum chemical study of silanediols as metal binding groups for metalloprotease inhibitors. J Mol Model (2013) 0.79
Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease. ACS Chem Neurosci (2015) 0.78
Design, Synthesis, and Evaluation of Polyamine Deacetylase Inhibitors, and High-Resolution Crystal Structures of Their Complexes with Acetylpolyamine Amidohydrolase. Biochemistry (2015) 0.78
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer. Oncotarget (2016) 0.78
Dietary manipulation of histone structure and function. World Rev Nutr Diet (2010) 0.78
Translating the histone code. Science (2001) 56.77
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 7.47
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov (2002) 6.97
Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol (2004) 6.00
Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol (2003) 5.92
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Metal-ligand geometry relevant to proteins and in proteins: sodium and potassium. Acta Crystallogr D Biol Crystallogr (2002) 3.55
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (2004) 3.31
Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol (1997) 2.73
Review: chromatin structural features and targets that regulate transcription. J Struct Biol (2000) 2.36
Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem (2000) 2.19
Histone deacetylase as a therapeutic target. Trends Endocrinol Metab (2001) 1.83
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol (2004) 1.60
Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J Biol Chem (2002) 1.52
Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques (2002) 1.52
The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol (2003) 1.38
Inhibition of thermolysin and carboxypeptidase A by phosphoramidates. Biochemistry (1979) 1.18
Activation of terminal B cell differentiation by inhibition of histone deacetylation. Mol Immunol (2003) 1.13
Peptide hydroxamic acids as inhibitors of thermolysin. Biochemistry (1978) 1.03
FT-IR study of the Ca2+-binding to bovine alpha-lactalbumin. Relationships between the type of coordination and characteristics of the bands due to the Asp COO- groups in the Ca2+-binding site. FEBS Lett (1997) 0.92
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology (2012) 3.12
The crystal structure of the quorum sensing protein TraR bound to its autoinducer and target DNA. EMBO J (2002) 3.11
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem (2003) 2.82
Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. J Biol Chem (2003) 2.72
Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol (2003) 2.63
Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol (2002) 2.61
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res (2007) 2.60
In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol (2003) 2.55
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol (2010) 2.25
Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat Immunol (2011) 2.11
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem (2008) 2.09
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep (2007) 2.01
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem (2007) 1.92
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A (2008) 1.80
Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology (2007) 1.74
Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J Virol (2004) 1.71
Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol (2004) 1.71
Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem (2005) 1.54
Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. J Invest Dermatol (2011) 1.51
Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood (2013) 1.42
Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem (2008) 1.41
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology (2011) 1.40
Antibody-drug conjugates in tumor therapy. Pharm Pat Anal (2012) 1.38
Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett (2008) 1.37
PP2A regulates HDAC4 nuclear import. Mol Biol Cell (2007) 1.34
A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem (2010) 1.32
Hepatitis C virus NS5A is a direct substrate of casein kinase I-alpha, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors. J Biol Chem (2006) 1.30
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res (2010) 1.29
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology (2012) 1.26
New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology (2013) 1.26
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res (2008) 1.26
Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. Circ Res (2007) 1.24
Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity. PLoS Pathog (2012) 1.23
Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry (2004) 1.21
The alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation. J Virol (2006) 1.19
Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J Med Chem (2004) 1.16
Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J Virol (2002) 1.15
Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling. J Biol Chem (2006) 1.15
A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg Med Chem Lett (2006) 1.10
2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg Med Chem Lett (2008) 1.08
A novel, inducible, eukaryotic gene expression system based on the quorum-sensing transcription factor TraR. EMBO Rep (2003) 1.06
HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis. J Med Chem (2004) 1.02
Characterization of prejunctional serotonin receptors modulating [3H]acetylcholine release in the human detrusor. J Pharmacol Exp Ther (2005) 1.01
Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J Med Chem (2005) 1.01
Naturally occurring hepatitis C virus subgenomic deletion mutants replicate efficiently in Huh-7 cells and are trans-packaged in vitro to generate infectious defective particles. J Virol (2009) 1.01
A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. Bioorg Med Chem Lett (2002) 1.00
From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Curr Pharm Des (2008) 1.00
HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antivir Chem Chemother (2005) 0.96
Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. J Med Chem (2005) 0.96
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J Med Chem (2012) 0.96
Studies on the mode of Ku interaction with DNA. J Biol Chem (2002) 0.96
Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. Biochim Biophys Acta (2007) 0.96
Crystal structure of the quorum-sensing protein TraM and its interaction with the transcriptional regulator TraR. J Biol Chem (2004) 0.95
Loss of histone deacetylase 4 causes segregation defects during mitosis of p53-deficient human tumor cells. Cancer Res (2009) 0.94
Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorg Med Chem Lett (2009) 0.94
Hepatitis C virus-specific directly acting antiviral drugs. Curr Top Microbiol Immunol (2013) 0.93
2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg Med Chem Lett (2008) 0.90
Recent developments in the discovery of hepatitis C virus serine protease inhibitors--towards a new class of antiviral agents? Expert Opin Investig Drugs (2003) 0.90
The monoethyl ester of meconic acid is an active site inhibitor of HCV NS5B RNA-dependent RNA polymerase. Bioorg Med Chem Lett (2004) 0.89
2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis. J Med Chem (2006) 0.89
Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors. J Med Chem (2009) 0.89
Molecular insights into azumamide e histone deacetylases inhibitory activity. J Am Chem Soc (2007) 0.87
A functionally orthogonal estrogen receptor-based transcription switch specifically induced by a nonsteroid synthetic ligand. Chem Biol (2005) 0.86
Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors. J Mol Biol (2009) 0.86